Brought to you by 
Spectrum sells injectable generics to Sagent
25 May 2022
Executive Summary
Sagent Pharmaceuticals (injectable therapeutics) has bought Spectrum Pharmaceuticals' (mainly focused on cancer and urology drugs) ANDAs for the injectable generic drugs ondansetron (nausea/vomiting), carboplatin (cancer), fludarabine (cancer), and mitoxantrone (multiple sclerosis).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spectrum sells injectable generics to Sagent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice